Requires hospitals to test for fentanyl and xylazine as part of urine drug screenings.

This bill requires New Jersey hospitals to include testing for fentanyl and xylazine in routine urine drug screenings when treating patients. It directly affects all general acute care hospitals licensed in New Jersey that conduct such screenings. Hospitals must report de-identified test results to the Department of Health if fentanyl, xylazine, or other drugs under a health alert are detected. The law aims to improve overdose response by ensuring these dangerous substances - linked to rising fatal overdoses - are identified during patient care.